Sponsored by Lonza AG

What is the state-of-the state for biomanufacturing (drug substance) in terms of industry capacity utilization, in-sourced/outsourced activity, and technology drivers? Is capacity in line with demand or is capacity tightening? How about for the make versus buy decision; is it trending upward or downward for CDMOs of biologics? And how does AI factor into current and future technology needs in bioprocessing, and what else tops the technology interests in both upstream and downstream bioprocessing?

In this episode, Eric Langer, Managing Partner & President, BioPlan Associates, Inc., a strategic consulting and business intelligence firm for the biopharmaceutical and life-sciences industries, provides key insights that need to be on your company’s radar.

Each episode of the Production to Prescription podcast is housed on the DCAT Value Chain Insights website and also delivered through DCAT Value Chain Insights weekly email digest. Not a subscriber? Click here to subscribe to DCAT Value Chain Insights, or get each episode through: 

For a full list of the 2026 podcast episode schedule, click here.